X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
GSBR-1290 is an orally-available small molecule agonist of the GLP-1 receptor, a validated drug target which is being evaluated for the treatment of Type 2 Diabetes Mellitus (T2DM) and obesity.
Lead Product(s): GSBR-1290
Therapeutic Area: Endocrinology Product Name: GSBR-1290
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 18, 2023
Details:
The net proceeds will be used to accelerate the development of GSBR-1290, an orally-available small molecule agonist of the GLP-1 receptor, a validated drug target for the treatment of T2DM and obesity.
Lead Product(s): GSBR-1290
Therapeutic Area: Endocrinology Product Name: GSBR-1290
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Jefferies
Deal Size: $300.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement September 29, 2023
Details:
GSBR-1290 is an orally-available small molecule agonist of the GLP-1 receptor, a validated drug target for the treatment of) T2DM and obesity. The Company is also planning a separate formulation bridging pharmacokinetic study to support the planned transition from capsules to tablets.
Lead Product(s): GSBR-1290
Therapeutic Area: Endocrinology Product Name: GSBR-1290
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 29, 2023
Details:
GSBR-1290 is an orally-available small molecule agonist of the GLP-1 receptor, a validated drug target for the treatment of) T2DM and obesity. The Company completed its Phase 1 single ascending dose (SAD) study in September 2022.
Lead Product(s): GSBR-1290
Therapeutic Area: Endocrinology Product Name: GSBR-1290
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 25, 2023
Details:
The Company intends to use the net proceeds from the offering primarily for the acceleration of the development of GSBR-1290, and supporting business development activities, and for general corporate purposes.
Lead Product(s): GSBR-1290
Therapeutic Area: Endocrinology Product Name: GSBR-1290
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Jefferies
Deal Size: $185.3 million Upfront Cash: Undisclosed
Deal Type: Public Offering February 07, 2023
Details:
Proceeds from financing will be used to advance lead programs, including GSBR-1290 in clinical investigation and expand application of its next generation structure-based drug discovery platform to drive innovations in G-protein coupled receptor targeted therapies.
Lead Product(s): GSBR-1290
Therapeutic Area: Endocrinology Product Name: GSBR-1290
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Deep Track Capital
Deal Size: $133.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing August 01, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
